These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 25887748)

  • 1. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children.
    Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
    BMC Infect Dis; 2015 Mar; 15():126. PubMed ID: 25887748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
    Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
    Int J Tuberc Lung Dis; 2016 May; 20(5):666-72. PubMed ID: 27084822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations.
    Verhagen LM; López D; Hermans PW; Warris A; de Groot R; García JF; de Waard JH; Aarnoutse RE
    Trop Med Int Health; 2012 Dec; 17(12):1449-56. PubMed ID: 23094704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of anti-TB drugs in Malawian children: reconsidering the role of ethambutol.
    Mlotha R; Waterhouse D; Dzinjalamala F; Ardrey A; Molyneux E; Davies GR; Ward S
    J Antimicrob Chemother; 2015; 70(6):1798-803. PubMed ID: 25759035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.
    Xu J; Jin H; Zhu H; Zheng M; Wang B; Liu C; Chen M; Zhou L; Zhao W; Fu L; Lu Y
    Clin Ther; 2013 Feb; 35(2):161-8. PubMed ID: 23410999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.
    Bekker A; Schaaf HS; Draper HR; van der Laan L; Murray S; Wiesner L; Donald PR; McIlleron HM; Hesseling AC
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2171-9. PubMed ID: 26810651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of First-Line Drugs Among Children With Tuberculosis in Rural Tanzania.
    Justine M; Yeconia A; Nicodemu I; Augustino D; Gratz J; Mduma E; Heysell SK; Kivuyo S; Mfinanga S; Peloquin CA; Zagurski T; Kibiki GS; Mmbaga B; Houpt ER; Thomas TA
    J Pediatric Infect Dis Soc; 2020 Feb; 9(1):14-20. PubMed ID: 30395239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses?
    Trentalange A; Borgogno E; Motta I; Antonucci M; Pirriatore V; Costa C; Rossi G; Barco A; De Nicolò A; Piccioni P; D'Avolio A; Bonora S; Di Perri G; Calcagno A
    Int J Antimicrob Agents; 2021 Mar; 57(3):106297. PubMed ID: 33539932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children.
    Ramachandran G; Hemanth Kumar AK; Bhavani PK; Poorana Gangadevi N; Sekar L; Vijayasekaran D; Banu Rekha VV; Ramesh Kumar S; Ravichandran N; Mathevan G; Swaminathan S
    Int J Tuberc Lung Dis; 2013 Jun; 17(6):800-6. PubMed ID: 23676165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.
    Thee S; Seddon JA; Donald PR; Seifart HI; Werely CJ; Hesseling AC; Rosenkranz B; Roll S; Magdorf K; Schaaf HS
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5560-7. PubMed ID: 21968358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics of a single oral or rectal dose of concurrently administered isoniazid, rifampin, pyrazinamide, and ethambutol in Asian elephants (Elephas maximus).
    P Brock A; Isaza R; Egelund EF; Hunter RP; Peloquin CA
    J Vet Pharmacol Ther; 2014 Oct; 37(5):472-9. PubMed ID: 24684601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis.
    Ruslami R; Gafar F; Yunivita V; Parwati I; Ganiem AR; Aarnoutse RE; Wilffert B; Alffenaar JC; Nataprawira HM
    Arch Dis Child; 2022 Jan; 107(1):70-77. PubMed ID: 34183327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of First-Line Anti-Tubercular Drugs.
    Mukherjee A; Lodha R; Kabra SK
    Indian J Pediatr; 2019 May; 86(5):468-478. PubMed ID: 30915644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.
    McIlleron H; Wash P; Burger A; Norman J; Folb PI; Smith P
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1170-7. PubMed ID: 16569826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status.
    Ramachandran G; Kumar AK; Kannan T; Bhavani PK; Kumar SR; Gangadevi NP; Banurekha VV; Sudha V; Venkatesh S; Ravichandran N; Kalpana S; Mathevan G; Sanjeeva GN; Agarwal D; Swaminathan S
    Pediatr Infect Dis J; 2016 May; 35(5):530-4. PubMed ID: 26825153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi.
    van Oosterhout JJ; Dzinjalamala FK; Dimba A; Waterhouse D; Davies G; Zijlstra EE; Molyneux ME; Molyneux EM; Ward S
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6175-80. PubMed ID: 26248378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children.
    Martial LC; Kerkhoff J; Martinez N; Rodríguez M; Coronel R; Molinas G; Roman M; Gomez R; Aguirre S; Jongedijk E; Huisman J; Touw DJ; Pérez D; Chaparro G; Gonzalez F; Aarnoutse RE; Alffenaar JW; Magis-Escurra C
    Int J Antimicrob Agents; 2018 Jul; 52(1):109-113. PubMed ID: 29751121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV Coinfection.
    Antwi S; Yang H; Enimil A; Sarfo AM; Gillani FS; Ansong D; Dompreh A; Orstin A; Opoku T; Bosomtwe D; Wiesner L; Norman J; Peloquin CA; Kwara A
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses.
    Zvada SP; Denti P; Donald PR; Schaaf HS; Thee S; Seddon JA; Seifart HI; Smith PJ; McIlleron HM; Simonsson US
    J Antimicrob Chemother; 2014 May; 69(5):1339-49. PubMed ID: 24486870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients.
    Tostmann A; Mtabho CM; Semvua HH; van den Boogaard J; Kibiki GS; Boeree MJ; Aarnoutse RE
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3208-13. PubMed ID: 23629715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.